1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial
    Journal Article

    Padrón, L. J.; Maurer, D. M.; O’Hara, M. H.; O’Reilly, E. M.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review
    Review

    Battisti, N. M. L.; De Glas, N.; Soto-Perez-de-Celis, E.; Liposits, G.; Bringuier, M.; Walko, C.; Lichtman, S. M.; Aapro, M.; Cheung, K. L.; Biganzoli, L.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
    Journal Article

    Janku, F.; Bauer, S.; Shoumariyeh, K.; Jones, R. L.; Spreafico, A.; Jennings, J.; Psoinos, C.; Meade, J.; Ruiz-Soto, R.; Chi, P.
    ESMO Open (2022)

    Fulltext@MSK | Save
  • Metformin for treatment of cytopenias in children and young adults with Fanconi anemia
    Journal Article

    Pollard, J. A.; Furutani, E.; Liu, S.; Esrick, E.; Cohen, L. E.; Bledsoe, J.; Liu, C. W.; Lu, K.; de Haro, M. J. R.; Surrallés, J.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial
    Journal Article

    Shanafelt, T. D.; Wang, X. V.; Hanson, C. A.; Paietta, E. M.; O'Brien, S.; Barrientos, J.; Jelinek, D. F.; Braggio, E.; Leis, J. F.; Zhang, C. C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Neoadjuvant systemic therapy (NAST) in patients with melanoma: Surgical considerations by the International Neoadjuvant Melanoma Consortium (INMC)
    Guidelines

    van Akkooi, A. C. J.; Hieken, T. J.; Burton, E. M.; Ariyan, C.; Ascierto, P. A.; Asero, S. V. M. A.; Blank, C. U.; Block, M. S.; Boland, G. M.; Caraco, C.; more...
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: A multicentre, open-label, phase 2 study
    Journal Article

    Zauderer, M. G.; Szlosarek, P. W.; Le Moulec, S.; Popat, S.; Taylor, P.; Planchard, D.; Scherpereel, A.; Koczywas, M.; Forster, M.; Cameron, R. B.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • A phase I study investigating AZD8186, a potent and selective inhibitor of PI3Kβ/δ, in patients with advanced solid tumors
    Journal Article

    Choudhury, A. D.; Higano, C. S.; de Bono, J. S.; Cook, N.; Rathkopf, D. E.; Wisinski, K. B.; Martin-Liberal, J.; Linch, M.; Heath, E. I.; Baird, R. D.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Central diabetes insipidus induced by acute myeloid leukemia with DNMT3A mutation
    Journal Article

    Lakshmanan, P.; Asnani, H.; Knorr, D.
    Case Reports in Endocrinology (2022)

    Fulltext@MSK | Save
  • A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND)
    Journal Article

    Harrison, M. R.; Davis, P. G.; Khouri, M. G.; Bartlett, D. B.; Gupta, R. T.; Armstrong, A. J.; McNamara, M. A.; Zhang, T.; Anand, M.; Onyenwoke, K.; more...
    Prostate Cancer and Prostatic Diseases (2022)

    Fulltext@MSK | Save